
RESULT OF RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS
Auction | Auction results |
Auction date | 2022-06-14 |
Maturity | 2027 |
Tendered volume, SEK mln | 500 +/- 500 |
Offered volume, SEK mln | 780 |
Volume bought, SEK mln | 0 |
Number of bids | 8 |
Number of accepted bids | 0 |
Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
Offered volume, SEK mln | 150 | 0 | 0 | 0 |
Volume bought, SEK mln | 0 | 0 | 0 | 0 |
Number of bids | 1 | 0 | 0 | 0 |
Number of accepted bids | 0 | 0 | 0 | 0 |
Average DM | - | - | - | - |
Lowest accepted DM | - | - | - | - |
Highest DM | - | - | - | - |
Accepted at lowest DM | - | - | - | - |
Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
Offered volume, SEK mln | 530 | 100 | 0 | 0 |
Volume bought, SEK mln | 0 | 0 | 0 | 0 |
Number of bids | 6 | 1 | 0 | 0 |
Number of accepted bids | 0 | 0 | 0 | 0 |
Average DM | - | - | - | - |
Lowest accepted DM | - | - | - | - |
Highest DM | - | - | - | - |
Accepted at lowest DM | - | - | - | - |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER30.6.2022 09:31:00 CEST | Press release
PRE ANNOUNCEMENT OF CERTIFICATE AUCTION TENDER MONETARY POLICY MEETING 2022-06-29 AUCTION PERIODS COMMENCING: 2022-07-06: FIXED RATE 0.75 % (VALID UNTIL NEXT MONETARY POLICY MEETING) DEPOSIT RATE 0.65 % LENDING RATE 0.85 %
Huhtamaki publishes 2022 Half-yearly Report on July 21, 202230.6.2022 09:00:00 CEST | Press release
HUHTAMÄKI OYJ PRESS RELEASE 30.6.2022 AT 10:00 Huhtamaki publishes 2022 Half-yearly Reporton July21, 2022 Huhtamäki Oyj will publish its 2022 Half-yearly Report on Thursday, July 21, 2022, approximately at 8.30 am Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined audiocast and teleconference on the same day at 9.30 am Finnish time, where the company’s management will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q2 If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland Toll: +358981710310 Sweden Toll: +46 856642651 United Kingdom Toll: +44 3333000804 United States Toll: +1 6319131422 Confirmation code for the call is 23337170# An on-demand replay of the audiocast w
Fingerprints announces design win for its optical under-display solution with major Asian smartphone OEM30.6.2022 08:00:00 CEST | Press release
Fingerprint Cards AB (Fingerprints™) today announced that it has secured a design win* for its optical under-display solution, FPC 1632, with a major Asian smartphone OEM, following successful qualification tests earlier this year. We expect to commence shipments during the fourth quarter of 2022. “Since many years, Fingerprints is a well-established world leader in capacitive fingerprint sensors. The design win we are announcing today marks our entry into a new market segment: optical under-display fingerprint sensors. This will open up attractive new growth opportunities for us going forward, and our goal is to capture a significant share of this market,” says Ted Hansson, President Mobile, PC & Access China at Fingerprints. For more information about Fingerprints’ mobile device solutions, visit the website. * Fingerprints’ definition of Design Win (DW): The decision by a device vendor (OEM or ODM) to start development of one or several commercial product(s) incorporating Fingerprint
Inaugural Yara Clean Ammonia Capital Markets Day30.6.2022 08:00:00 CEST | Press release
Oslo, 30 June 2022: Today, Yara International ASA (“Yara”) will host a Capital Markets Day (“CMD”) for Yara Clean Ammonia (“YCA” or the “Company”). During the event, members of YCA’s management team will present key features of the Company, including its strategy and growth ambitions, as well as financial parameters and targets for the future. In May 2022, Yara announced that it is evaluating a potential initial public offering (“IPO”) of YCA on the Oslo Stock Exchange. “While the decision to list YCA will be made in due course, Yara is now excited to host an inaugural CMD for YCA to showcase their exciting story,” said Svein Tore Holsether, CEO and President of Yara. “YCA combines a leading midstream business with exceptional growth prospects and a value creating project portfolio.” Key highlights: Clean ammonia represents a massive opportunity that is projected to drive exponential, long-term market growth [1].YCA comprises existing cash flows from a market leading position [2] in a
Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma30.6.2022 08:00:00 CEST | Press release
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 monthsStudy provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces the completed recruitment of 154 patients in the INITIUM trial. INITIUM is Ultimovacs’ Phase II clinical trial of its universal cancer vaccine UV1 in combination with the checkpoint inhibitors ipilimumab and nivolumab in metastatic malignant melanoma. Consistent with INITIUM’s event-driven design, topline progression-free survival results will be disclosed after progression of cancer or death has been observed in a total of 70 patients. “It is a remarkable achievement that Ultimovacs and its clinical partners have completed recruitment to INITIUM largely on schedule despite challenges caused by the pandemic,” said Carlos de Sou